Stu d ies on Qu in a zolin es. 11.†
In tr a m olecu la r Im id a te-Am id e
Rea r r a n gem en t of 2-Su bstitu ted
of our studies on quinazoline derivatives as R1-adreno-
ceptors,14 we designed and synthesized a series of 2-sub-
stituted 3-(4-arylpiperazinyl)alkylquinazolin-4(3H)-one
derivatives.
There are numerous methods available for the syn-
thesis of quinazolinones and their derivatives.15 Reports
on solid-phase synthesis of related quinazolinones16 are
an additional impetus to explore their multifaceted
importance. We adapted the procedure of direct cyclo-
condensation dehydrogenation17 of anthranilamide with
benzoic anhydride and phenylacetyl chloride to prepare
our starting materials, 2-phenyl- (1) and 2-benzylquinazo-
lin-4(3H)-one (2), respectively.
4-(ω-Ch lor oa lk oxy)qu in a zolin e Der iva tives.
1,3 -O f N Sh ift of Ch lor oa lk yl Gr ou p s via
Cyclic 1,3-Aza oxon iu m In ter m ed ia tes
Grace Shiahuy Chen, Shivaramayya Kalchar,
Chun-Wei Kuo, Chih-Shiang Chang,
Cyril O. Usifoh, and J i-Wang Chern*
School of Pharmacy, College of Medicine, National Taiwan
University, No. 1, Section 1, J en-Ai Road, Taipei 100,
Taiwan, Republic of China
For the preparation of our potential target compounds,
first 1 was treated with ω-chloroethyl bromide in K2CO3/
DMF at room temperature, but unexpectedly it only led
to the O-alkylated product 4a instead of our desired key
intermediate 3a . Nevertheless, when the reaction was
carried out at higher temperature, it was found that the
N-alkylated derivative 3a was the only product. A perusal
of literature indicated that the N-/O-alkylation of het-
erocyclic ambident nucleophiles has been broadly stud-
ied.18 A percentage of about 35:65 for the N-/O-propargyl
products of 1 and no O-alkylation for the corresponding
2-benzyl derivative (2) were reported by two independent
groups.19 To probe this matter, we carried out the
chern@jwc.mc.ntu.edu.tw
Received August 22, 2002
Abstr a ct: The ω-chloroalkylation of 2-substituted quinazo-
lin-4(3H)-one derivatives 1 and 2 with Br-(CH2)n-Cl (n )
2-4) and the intramolecular imidate-amide rearrangement
of the alkylated products are described. At room tempera-
ture, the 2-phenyl substituent promoted O-alkylation, whereas
the less steric 2-benzyl group led to a higher ratio of
N-alkylation. The investigation of the O-alkylated products,
4-ω-chloroalkoxyquinazolines, revealed that the migration
of ω-chloroethyl and ω-chloropropyl groups from oxygen to
nitrogen should be intramolecular via five- and six-mem-
bered cyclic 1,3-azaoxonium intermediates, respectively.
Competition between rearrangement and nucleophilic sub-
stitution results in the formation of 7a ,b and 8a ,b from the
nucleophilic substitution of 4a ,b and 6a ,b, respectively.
(8) Matsuno, K.; Ichimura, M.; Nakajima, T.; Tahara, K.; Fujiwara,
S.; Kase, H.; Ushiki, J .; Giese, N. A.; Pandey, A.; Scarborough, R. M.;
Lokker, N. A.; Yu, J .-C.; Irie, J .; Tsukuda, E.; Ide, S.-i.; Oda, S.; Nomoto,
Y. J . Med. Chem. 2002, 45, 3057.
(9) Srivastava, B.; Shukla, J . S. Indian J . Chem., Sect. B 1991, 30B,
332.
(10) Fetter, J .; Czuppo, T.; Hornyak, G.; Feller, A. Tetrahedron 1991,
47, 9393.
4(3H)-Quinazoline derivatives1 possess a broad spec-
trum of biological activities such as antidiabetic,2 anti-
convulsant,3 analgesic,4 antibacterial,5 protein tyrosine
kinase inhibitors,6 EGFR inhibitors,7 PDGFR phospho-
rylation inhibitors,8 CNS depressants,9 and antitumor
activity.10 Furthermore, the heterocyclic core constitutes
more than 40 alkaloids11 isolated from natural products,
and some show interesting biological profiles such as
antimalarial12 and diuretic13 properties. In continuation
(11) (a) Katritzky, A. R.; Rees, C. W. Comprehensive Heterocyclic
Chemistry. The Structure, Reaction, Synthesis and Uses of Heterocyclic
Compounds; Pergamon Press: New York, 1984; Vol. 3, Part 2B. (b)
Pelletier, S. W. Alkaloids: Chemical and Biological Prospective; J ohn
Wiley & Sons Ltd.: New York, 1983; Vol. 1. (c) J ohne, S. Alkaloids
1986, 29, 99.
(12) Abdel-Rahman, M. M.; Mangoura, S. A.; Ei-Bitar, H. I. Bull.
Pharm. Sci. 1990, 13, 137.
(13) He, F.; Snider, B. B. J . Org. Chem. 1999, 64, 1397.
(14) (a) Chern, J .-W.; Lo, J .-C.; Lin, H.-M.; Cheng, F.-C.; Usifoh, C.
O. Chin. Pharm. J . 1999, 51, 3. (b) Chern, J .-W.; Tao, P. L.; Wang, K.
C.; Gutcait, A.; Liu, S. W.; Yen, M. H.; Chien, S. L.; Rong, J . K. J .
Med. Chem. 1998, 41, 3128. (c) Chern, J .-W.; Tao, P. L.; Yen, M. H.;
Lu, G. Y.; Shiou, C. Y.; Lai, Y. J .; Chien, S. L.; Chan, C. H. J . Med.
Chem. 1993, 36, 2196.
(15) (a) Lange, N. A.; Sheibley, F. E. Org. Synth. 1943, 2, 9. (b)
Kornet, M. J .; Varia, T.; Beaven, W. J . Heterocycl. Chem. 1984, 21,
1533. (c) Couture, A.; Cornet, H. Grandclaudon, P. Synthesis 1991,
1009. (d) Minami, T.; Ogata, M.; Hirao, I. Synthesis 1982, 231. (e)
Canonne, P.; Aksssira, M.; Dahdouh, A.; Kasmi, H.; Boumzebra, M.
Heterocycles 1993, 36, 1305. (f) Papadopoulos, E. P. J . Heterocycl.
Chem. 1981, 18, 515. (g) Al-Talib, M.; J ochims, J . C.; Hamed, A.; Wang,
Q.; Ismail, A. E. Synthesis 1992, 697. (h) Connolly, D. J .; Guiry, P. J .
Synlett 2001, 1707. (i) Xu, X.; Lu, P.; Zhang, Y. Synth. Commun. 2001,
31, 323.
(16) (a) Buckman, R. O.; Mohan, R. Tetrahedron Lett. 1996, 37, 4439.
(b) Mayer, J . P.; Lewis, G. S.; Curits, M. J .; Zhang, J . Tetrahedron
Lett. 1997, 38, 8445. (c) Gopalsamy, A.; Yang, H. J . Comb. Chem. 2000,
2, 378.
(17) Imai, Y.; Sato, S.; TAkasawa, R.; Ueda, M. Synthesis 1981, 35.
(18) (a) Gallo, R. J .; Makosza, M.; Dou, H. J . M.; Hassanaly, P. Adv.
Heterocycl. Chem. 1984, 36, 175. (b) Usifoh, C. O. J . Heterocycl. Chem.
2001, 38, 597. (c) Hartung, J .; Kneuer, R.; Schwarz, M.; Svoboda, I.;
Fuess, H. Eur. J . Org. Chem. 1999, 97.
† For part 10, see ref 14a.
(1) (a) Armarego, W. L. F. Adv. Heterocycl. Chem. 1963, 1, 253. (b)
Armarego, W. L. F. Adv. Heterocycl. Chem. 1979, 24, 1. (c) Ellis, G. P.
Synthesis of Fused Heterocycles; J ohn Wiley & Sons Ltd.: Chichester,
1987, Vol. 47.
(2) Malamas, M. S.; Millen, J . J . Med. Chem. 1991, 34, 1492.
(3) (a) Mannschreck, A.; Koller, H.; Stuhler, G.; Davies, M. A.;
Traber, J . Eur. J . Med. Chem. 1984, 19, 381. (b) Gupta, C. M.; Bhaduri,
A. P.; Khanna, N. M. J . Med. Chem. 1968, 11, 392.
(4) Fisnerova, L.; Brunova, B.; Kocfeldova, Z.; Tikalova, J .; Matur-
ova, E.; Grimova, J . Collect. Czech Chem. Commun. 1991, 56, 2373.
(5) Kung, P.-P.; Casper, M. D.; Cook, K. L.; Wilson-Lingard, L.;
Risen, L. M.; Vickers, T. A.; Ranken, R.; Blyn, L. B.; Wyatt, J . R.; Cook,
P. D.; Ecker, D. J . J . Med. Chem. 1999, 42, 4705.
(6) (a) Sharma, S. D.; Kaur, V. Synthesis 1989, 677. (b) Palmer, B.
D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J . M.; Showalter, H. D.
H.; Denny, W. A. J . Med. Chem. 1997, 40, 1519.
(7) (a) Tsou, H.-R.; Mamuya, N.; J ohnson, B. D.; Reich, M. F.;
Gruber, B. C.; Ye, F.; Nilakantan, R.; Shen, R.; Discafani, C.; DeBlanc,
R.; Davis, R.; Koehn, F. E.; Greenberger, L. M.; Wang, Y.-F.; Wissner,
A. J . Med. Chem. 2001, 44, 2719. (b) Smaill, J . B.; Rewcastle, G. W.;
Loo, J . A.; Greis, K. D.; Chan, H.; Reyner, E. L.; Lipka, E.; Showalter,
H. D. H.; Vincent, P. W.; Elliott, W. L.; Denny, W. A. J . Med. Chem.
2000, 43, 1380 and references therein.
(19) (a) Bogentoft, C.; Kronberg, L.; Danielsson, B. Acta Pharm.
Suecica 1969, 6, 489. (b) Usifoh, C. O.; Scriba, G. K. E. Arch. Pharm.
Pharm. Med. Chem. 2000, 333, 261.
10.1021/jo0263420 CCC: $25.00 © 2003 American Chemical Society
Published on Web 02/14/2003
2502
J . Org. Chem. 2003, 68, 2502-2505